Citations

Clear

861 citation(s) found for "Sd, Wexner".

It’s About Time! Timing in Epilepsy Evaluation and Treatment
McKee, Heather , Vidaurre, Jorge , Clarke, Dave , Wagner, Janelle L. , Britton, Jeffrey W. , Laux, Linda , Trinka, Eugen , Rubiños, Clio , Bebin, Martina , Maciel, Carolina B. , Chandran, Arjun , Tandon, Nitin , Vaca, Guadalupe Fernández‐Baca, Moosa, Ahsan N. , McKee, Heather Ravvin , Wagner, Janelle , Britton, Jeffrey W , Berl, Madison , Trinka, Eugen , Vidaurre, Jorge , Tandon, Nitin , McDonald, Tanya J. W. , Lado, Fred Alexander , Papadelis, Christos , Struck, Aaron F. , Velasco, Ana Luisa , Pati, Sandipan Bankim Behari , Berl, Madison M.

Mayo Clinic

Epilepsy Currents | April 1, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15357597241238072 | PMID 39554272 Get It

The 2023 American Epilepsy Society Annual Course “It’s About Time” addressed timing in epilepsy evaluation and treatment with respect to health disparity and vulnerable populations and diagnostic, clinical, and epilepsy surgery evaluation. This comprehensive course included topics on gaps in epilepsy care and optimization of behavioral health for patients with epilepsy. The summary details current knowledge in areas of seizure forecasting and epileptogenesis. Intricacies and controversies over timing were discussed for treatment of nonconvulsive seizures and ictal-interictal patterns, acute symptomatic seizures, neuromodulation versus surgery, and epilepsy surgery in status epilepticus. Timing regarding clinical care in autoimmune-associated epilepsy, developmental and epileptic encephalopathy, and dietary therapy were examined. Additionally, salient topics on using novel biomarkers and collaboration with neuropsychological outcomes were also tackled in this all-encompassing lecture series.
The current state of training in pain medicine fellowships: An Association of Pain Program Directors ( APPD ) survey of program directors
Wahezi, Sayed , Caparó, Moorice , Choi, Heejung , Eshraghi, Yashar , Naeimi, Tahereh , Kohan, Lynn , Anițescu, Magdalena , Wright, Thelma , Przkora, Rene , Patel, Kiran V., Lamer, Tim J. , Moeschler, Susan M. , Yener, Ugur , Alerte, Jonathan, Grandhe, Radhika, Bautista, Alexander , Spektor, Boris , Noon, Kristen , Reddy, Rajiv , Osuagwu, Uzondu, Carpenter, A. Alden, Gerges, Frederic J., Murphy, Casey, Kim, Chong , Marshall, Cameron, Kirchen, Gwynne, Oryhan, Christine , Singh, Tejinder S. Swaran, Lubenow, Timothy R. , Sehgal, Nalini , Argoff, Charles E. , Gulati, Amit , Day, Miles, Sibai, Nabil, Dua, Anterpreet, Barad, Meredith , Singh, Tarun D. , Osuagwu, Uchechukwu Levi , Emerick, Trent D , Naeimi, Tahereh , Moeschler, Susan, Yener, Ugur , Bautista, Alexander , Reddy, Rajiv , Barad, Meredith J , Horn, Danielle Bodzin , Pritzlaff, Scott , Marshall, Cameron, Singh, Tejinder S. Swaran, Sayed, Dawood , Shaparin, Naum

Mayo Clinic

Pain Practice | March 30, 2024 | Volume: 24 | Issue: 7 | Pages: 895-903

10.1111/papr.13373 | PMID 38553945 Get It

Abstract Introduction The Accreditation Council for Graduate Medical Education (ACGME) approved the first pain medicine fellowship programs over three decades ago, designed around a pharmacological philosophy. Following that, there has been a rise in the transition of pain medicine education toward a multidisciplinary interventional model based on a tremendous surge of contemporaneous literature in these areas. This trend has created variability in clinical experience and education amongst accredited pain medicine programs with minimal literature evaluating the differences and commonalities in education and experience of different pain medicine fellowships through Program Director (PD) experiences. This study aims to gather insight from pain medicine fellowship program directors across the country to assess clinical and interventional training, providing valuable perspectives on the future of pain medicine education. Methods This study involved 56 PDs of ACGME‐accredited pain fellowship programs in the United States. The recruitment process included three phases: advanced notification, invitation, and follow‐up to maximize response rate. Participants completed a standard online questionnaire, covering various topics such as subcategory fields, online platforms for supplemental education, clinical experience, postgraduate practice success, and training adequacy. Results Surveys were completed by 39/56 (69%) standing members of the Association of Pain Program Directors (APPD). All PDs allowed fellows to participate in industry‐related and professional society‐related procedural workshops, with 59% encouraging these workshops. PDs emphasized the importance of integrity, professionalism, and diligence for long‐term success. Fifty‐four percent of PDs expressed the need for extension of fellowship training to avoid supplemental education by industry or pain/spine societies. Conclusion This study highlights the challenge of providing adequate training in all Pain Medicine subtopics within a 12‐month pain medicine fellowship. PDs suggest the need for additional training for fellows and discuss the importance of curriculum standardization.
Hypofractionated Stereotactic Radiosurgery in the Management of Brain Metastases
Lehrer, Eric J. , Breen, William G. , Singh, Raj , Brown, Paul D. , Sheehan, Jason P. , Palmer, Joshua D. , Trifiletti, Daniel M.

Mayo Clinic

Neurosurgery | March 21, 2024 | Volume: 95 | Issue: 2 | Pages: 253-258

10.1227/neu.0000000000002897 | PMID 38511946 Get It

Stereotactic radiosurgery (SRS) is an important weapon in the management of brain metastases. Single-fraction SRS is associated with local control rates ranging from approximately 70% to 100%, which are largely dependent on lesion and postoperative cavity size. The rates of local control and improved neurocognitive outcomes compared with conventional whole-brain radiation therapy have led to increased adoption of SRS in these settings. However, when treating larger targets and/or targets located in eloquent locations, the risk of normal tissue toxicity and adverse radiation effects within healthy brain tissue becomes significantly higher. Thus, hypofractionated SRS has become a widely adopted approach, which allows for the delivery of ablative doses of radiation while also minimizing the risk of toxicity. This approach has been studied in multiple retrospective reports in both the postoperative and intact settings. While there are no reported randomized data to date, there are trials underway evaluating this paradigm. In this article, we review the role of hypofractionated SRS in the management of brain metastases and emerging data that will serve to validate this treatment approach. Pertinent articles and references were obtained from a comprehensive search of PubMed/MEDLINE and clinicaltrials.gov.
Finding diamonds in the rough: evaluating the quality of meta-analyses in chronic pain – an infographic
Hussain, Nasir , D’Souza, Ryan S. , D'Souza, Ryan S

Mayo Clinic

Regional Anesthesia & Pain Medicine | March 19, 2024 | Volume: 50 | Issue: 5 | Pages: 437-438

10.1136/rapm-2024-105447 | PMID 38508590 Get It

Immunoprofiles and Oncologic Outcomes of 15 Patients with Androgen Receptor-Positive Salivary Duct Carcinoma
Gogineni, Emile , Sells, Blake , Dibs, Khaled , Jhawar, Sachin R. , Limbach, Abberly Lott , Konieczkowski, David J. , Jun, Sung , Baliga, Sujith , Mitchell, Darrion , Grecula, J.C., Bonomi, Marcelo , Bhateja, Priyanka, Old, Matthew , Seim, Nolan B. , Kang, Stephen Y. , Rocco, James W. , Chakravarti, Arnab , Blakaj, Dukagjin , Gamez, Mauricio E. , Sells, Blake E , Ma, Sung J , Mitchell, Darrion L , Bonomi, Marcelo , Bhateja, Priyanka , Jhawar, Sachin R , Chakravarti, Arnab , Haring, Catherine T. , Zhu, Simeng

Mayo Clinic

Cancers | March 19, 2024 | Volume: 16 | Issue: 6 | Pages: 1204

10.3390/cancers16061204 | PMID 38539538 Get It

Background: Salivary duct carcinomas (SDC) are a rare and aggressive subtype of salivary gland neoplasm. They can present with distinct immunoprofiles, such as androgen receptor (AR) and HER-2/Neu-positivity. To date, no consensus exists on how to best manage this entity. Methods: All patients diagnosed with nonmetastatic AR+ SDC of the parotid from 2013 to 2019 treated with curative intent were included. Immunologic tumor profiling was conducted using 24 distinct markers. Kaplan–Meier analyses were used to estimate locoregional recurrence (LRR), distant control, and overall survival (OS). Results: Fifteen patients were included. Nine (60%) patients presented with T4 disease and eight (53%) had positive ipsilateral cervical lymphadenopathy. Ten (67%) patients underwent trimodality therapy, including surgery followed by adjuvant radiation and concurrent systemic therapy. The median follow-up was 5.5 years (interquartile range, 4.8–6.1). The estimated 5-year rates of LRR, distant progression, and OS were 6%, 13%, and 87%, respectively. Conclusion: Despite only including AR+ SDC of the parotid, immunoprofiles, such as expression of HER-2, were highly variable, highlighting the potential to tailor systemic regimens based on individual histologic profiles in the future. Studies with larger patient numbers using tumor-specific molecular profiling and tumor heterogeneity analyses are justified to better understand the biology of these tumors. Molecularly informed treatment approaches, including the potential use of AR- and HER-2/Neu-directed therapies upfront in the definitive setting, may hold future promise to further improve outcomes for these patients.
Lifetime cost-effectiveness analysis osseointegrated transfemoral versus socket prosthesis using Markov modelling
Voigt, Jeffrey , Melton, Danielle , Hsu, Joseph R. , Voigt, Jeffrey D , Wilke, Benjamin, Potter, Benjamin Kyle , Souza, Jason M. , Forsberg, Jonathan Agner , Wilke, Benjamin K.

Mayo Clinic

Bone & Joint Open | March 15, 2024 | Volume: 5 | Issue: 3 | Pages: 218-226

10.1302/2633-1462.53.bjo-2023-0089.r1 | PMID 38484760 Get It

AimsPrior cost-effectiveness analyses on osseointegrated prosthesis for transfemoral unilateral amputees have analyzed outcomes in non-USA countries using generic quality of life instruments, which may not be appropriate when evaluating disease-specific quality of life. These prior analyses have also focused only on patients who had failed a socket-based prosthesis. The aim of the current study is to use a disease-specific quality of life instrument, which can more accurately reflect a patient’s quality of life with this condition in order to evaluate cost-effectiveness, examining both treatment-naïve and socket refractory patients.MethodsLifetime Markov models were developed evaluating active healthy middle-aged male amputees. Costs of the prostheses, associated complications, use/non-use, and annual costs of arthroplasty parts and service for both a socket and osseointegrated (OPRA) prosthesis were included. Effectiveness was evaluated using the questionnaire for persons with a transfemoral amputation (Q-TFA) until death. All costs and Q-TFA were discounted at 3% annually. Sensitivity analyses on those cost variables which affected a change in treatment (OPRA to socket, or socket to OPRA) were evaluated to determine threshold values. Incremental cost-effectiveness ratios (ICERs) were calculated.ResultsFor treatment-naïve patients, the lifetime ICER for OPRA was $279/quality-adjusted life-year (QALY). For treatment-refractory patients the ICER was $273/QALY. In sensitivity analysis, the variable thresholds that would affect a change in the course of treatment based on cost (from socket to OPRA), included the following for the treatment-naïve group: yearly replacement components for socket > $8,511; cost yearly replacement parts OPRA < $1,758; and for treatment-refractory group: yearly replacement component for socket of > $12,467.ConclusionThe use of the OPRA prosthesis in physically active transfemoral amputees should be considered as a cost-effective alternative in both treatment-naïve and treatment-refractory socket prosthesis patients. Disease-specific quality of life assessments such as Q-TFA are more sensitive when evaluating cost-effectiveness.Cite this article: Bone Jt Open 2024;5(3):218–226.
Reply to Kidd et al., “Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion”
Walsh, Thomas J. , Ahmed, Sarah , Alastruey‐Izquierdo, Ana , Alexander, Barbara D. , Arendrup, Maiken Cavling , Babady, Esther , Balada-Llasat, Joan-Miquel, Borman, Andrew M. , Colgrove, Robert C. , Cornely, Oliver A. , Fuller, Jeff, Gibas, Connie Fe C., Glasgow, Heather, Groll, Andreas H. , Haase, Gerhard , Hanson, Kimberly E. , Harrington, Amanda, Hayden, Randall T. , Hubka, Vít , Johnson, Kristie, Li, Ruoyu , Lanternier, Fanny , Lee, Francesca , Luethy, Paul M. , Kwon‐Chung, Kyung J., Palavecino, Elizabeth , Pancholi, Preeti , Pappas, Peter G. , Procop, Gary W. , Rhoads, Daniel D. , Riedel, Stefan , Stevens, Bryan S. , Sullivan, Kaede Ota, Vergidis, Paschalis , Roilides, Emmanuel , Seyedmousavi, Amir, Tao, Lili , Vicente, Vânia Aparecida , Vitale, Roxana G. , Wengenack, Nancy L. , Westblade, Lars F. , White, Lewis, Wojewoda, Christina , Babady, N. Esther , Seyedmousavi, Seyedmojtaba , de Hoog, Sybren , Walsh, Thomas J , Alastruey-Izquierdo, A , Arendrup, Maiken Cavling , Borman, Andrew , Groll, Andreas H , Hanson, Kimberly , Hayden, Randall T , Hoenigl, Martin , Kus, Julianne V , Meis, Jacques F , Leal, Sixto M , Lockhart, Shawn R. , Kwon-Chung, Kyung J , Nguyen, M Hong , Palavecino, Elizabeth , Pancholi, Preeti , Rhoads, Daniel D , Riedel, Stefan , Vergidis, Paschalis , Roilides, Emmanuel , Wengenack, Nancy L , Wiederhold, Nathan , White, Lewis , Wojewoda, Christina M , Zhang, Sean X , Cornely, Oliver A , Ahmed, Sarah A , Luethy, Paul , Bai, Feng‐Yan , Chowdhary, Anuradha , Clark, Andrew, Dingle, Tanis C. , Dufresne, Philippe J. , Gangneux, Jean‐Pierre , Gräser, Yvonne , Guillot, Jacques , Hawksworth, David L. , Hoenigl, Martin , Kus, Julianne V. , Lackner, Michaela , Leal, Sixto M. , Martin, Isabella W. , Meyer, Wieland , Ostrosky‐Zeichner, Luis , Redhead, Scott A. , Stevens, Bryan, Wang, Qiming , Wiederhold, Nathan P. , Zhang, Sean X.

Mayo Clinic

Journal of Clinical Microbiology | March 5, 2024 | Volume: 62 | Issue: 4 | Pages: No page available

10.1128/jcm.01625-23 | PMID 38441056 Get It

Palliative Quad Shot Radiation Therapy with or without Concurrent Immune Checkpoint Inhibition for Head and Neck Cancer
Upadhyay, Rituraj , Gogineni, Emile , Tocaj, Glenis , Bonomi, Marcelo , Bhateja, Priyanka, Konieczkowski, David J. , Baliga, Sujith , Mitchell, Darrion , Jhawar, Sachin R. , Grecula, J.C., Dibs, Khaled , Gamez, Mauricio E. , Blakaj, Dukagjin , Bonomi, Marcelo , Bhateja, Priyanka , Mitchell, Darrion L , Jhawar, Sachin R , Ma, Sung J., Zhu, Simeng

Mayo Clinic

Cancers | March 5, 2024 | Volume: 16 | Issue: 5 | Pages: 1049

10.3390/cancers16051049 | PMID 38473406 Get It

Objectives: Patients with recurrent and metastatic head and neck cancer (HNC) have limited treatment options. ‘QuadShot’ (QS), a hypofractionated palliative radiotherapy regimen, can provide symptomatic relief and local control and may potentiate the effects of immune checkpoint inhibitors (ICIs). We compared outcomes of QS ± concurrent ICIs in the palliative treatment of HNC. Materials and Methods: We identified patients who received ≥three cycles of QS from 2017 to 2022 and excluded patients without post-treatment clinical evaluation or imaging. Outcomes for patients who received QS alone were compared to those treated with ICI concurrent with QS, defined as receipt of ICI within 4 weeks of QS. Results: Seventy patients were included, of whom 57% received concurrent ICI. Median age was 65.5 years (interquartile range [IQR]: 57.9–77.8), and 50% patients had received prior radiation to a median dose of 66 Gy (IQR: 60–70). Median follow-up was 8.8 months. Local control was significantly higher with concurrent ICIs (12-month: 85% vs. 63%, p = 0.038). Distant control (12-month: 56% vs. 63%, p = 0.629) and median overall survival (9.0 vs. 10.0 months, p = 0.850) were similar between the two groups. On multivariable analysis, concurrent ICI was a significant predictor of local control (HR for local failure: 0.238; 95% CI: 0.073–0.778; p = 0.018). Overall, 23% patients experienced grade 3 toxicities, which was similar between the two groups. Conclusions: The combination of QS with concurrent ICIs was well tolerated and significantly improved local control compared to QS alone. The median OS of 9.4 months compares favorably to historical controls for patients with HNC treated with QS. This approach represents a promising treatment option for patients with HNC unsuited for curative-intent treatment and warrants prospective evaluation.
Novel radiotherapeutic strategies in the management of brain metastases: Challenging the dogma
Perlow, Haley K. , Lehrer, Eric J. , Wardak, Zabi , Soliman, Hany , Palmer, Joshua D , Perlow, Haley K , Palmer, Joshua D.

Mayo Clinic

Neuro-Oncology | March 4, 2024 | Volume: 26 | Issue: Supplement_1 | Pages: S46-S55

10.1093/neuonc/noad260 | PMID 38437668 Get It

Abstract The role of radiation therapy in the management of brain metastasis is evolving. Advancements in machine learning techniques have improved our ability to both detect brain metastasis and our ability to contour substructures of the brain as critical organs at risk. Advanced imaging with PET tracers and magnetic resonance imaging-based artificial intelligence models can now predict tumor control and differentiate tumor progression from radiation necrosis. These advancements will help to optimize dose and fractionation for each patient’s lesion based on tumor size, histology, systemic therapy, medical comorbidities/patient genetics, and tumor molecular features. This review will discuss the current state of brain directed radiation for brain metastasis. We will also discuss future directions to improve the precision of stereotactic radiosurgery and optimize whole brain radiation techniques to improve local tumor control and prevent cognitive decline without forming necrosis.
Performance of CT With Adrenal-Washout Protocol in Heterogeneous Adrenal Nodules: A Multiinstitutional Study
Corwin, Michael T. , Caoili, Elaine M. , Elsayes, Khaled M. , Garratt, Joanie , Hackett, Caitlin E. , Mohd, Zahid, Sharbidre, Kedar , Yalon, Mariana , Navin, Patrick J. , Hudson, Emma, Mohd, Zahid, Shehata, Mostafa , Wang, Mindy X. , Wilson, Machelle , Remer, Erick M.

Mayo Clinic

American Journal of Roentgenology | February 28, 2024 | Volume: 222 | Issue: 5 | Pages: No page available

10.2214/ajr.23.30769 | PMID 38415578 Get It